The addition of an immunotherapy may prevent serious hearing damage related to radiotherapy that treats tumors associated with neurofibromatosis 2 (NF2), according to a study published by PNAS Plus.
The researchers found that crizotinib inhibited a molecular pathway that improved the radiosensitivity of tumors in mice models of the genetic disease, which lead to a reduced dose. The treatment also was observed to stop the growth of cultured cancer cells from patients with NF2.
Additionally, the authors developed a new mouse model that better mimics NF2 hearing loss and a system for culturing NF2 tumor cells.
“The hallmark of NF2 are intracranial tumors called vestibular schwannomas, which typically lead to profound hearing loss,” said co-corresponding author Lei Xu, MD, PhD. “For most patients, hearing loss is the most disabling symptom of these tumors, and the primary treatments for growing tumors—surgery and radiation therapy—can further damage hearing. The development of a novel therapeutic strategy with enhanced efficacy and minimal treatment-related hearing loss is urgently needed… Continue reading....
WASHINGTON, DC: This year’s National Medal of Science winner Rakesh K. Jain said he was thrilled to receive the prestigious award from President Barack Obama.
“It’s an absolute thrill to receive this from President Obama,” he remarked from a general press podium outside of the White House just moments after the award ceremony. “He is really one of my heroes.”
Jain, a professor at Harvard Medical School and Massachusetts General Hospital, was one of the 17 individuals who received the National Medal of Science and the National Medal of Technology and Innovation from Obama at the White House on May 19.
Jain also offered a poignant nugget of advice to any young Indian Americans who find themselves drawn to STEM fields.
“Follow your passion,” he said. “Do what your heart and mind what you to and work hard. If you work hard and you’re passionate about something, you’re going to get there. That’s my thinking.”...